Remitió Ruben Piacentini
By Kelly Young
– Susan Sadoughi, MD, and
– Andre Sofair, MD, MPH
The National Institutes of Health COVID-19 Treatment Guidelines Panel now recommends that outpatients with mild-to-moderate COVID-19 at high risk for clinical progression be given either of these monoclonal antibody combinations:
— Bamlanivimab (700 mg) plus etesevimab (1400 mg)
— Casirivimab (1200 mg) plus imdevimab (1200 mg)
The panel notes that some SARS-CoV-2 variants have shown to be less susceptible to monoclonal antibodies, particularly bamlanivimab, in vitro, but it isn’t known what the clinical implications might be. Because of these concerns, the panel recommends against bamlanivimab monotherapy. Some panel members said that in areas where variants with reduced in vitro susceptibility to bamlanivimab and etesevimab are common, it would be reasonable to choose casirivimab plus imdevimab.
In other COVID-19 news, the FDA now says that facilities should limit their decontamination of disposable respirators given the increased supply of domestic respirators.
NIH statement on treatment guidelines (Free) http://response.jwatch.org/t?ctl=9E87E:AA579CC6C4DC3B7A89DBC2B4F1A22E2FD2B71D9A95FA21D3&
FDA letter to health care workers (Free) http://response.jwatch.org/t?ctl=9E87F:AA579CC6C4DC3B7A89DBC2B4F1A22E2FD2B71D9A95FA21D3&
NEJM Journal Watch COVID-19 page (Free) http://response.jwatch.org/t?ctl=9E880:AA579CC6C4DC3B7A89DBC2B4F1A22E2FD2B71D9A95FA21D3&
NEJM COVID-19 page (Free) http://response.jwatch.org/t?ctl=9E881:AA579CC6C4DC3B7A89DBC2B4F1A22E2FD2B71D9A95FA21D3&